AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Zelsuvmi (berdazimer topical gel)	Page:	1 of 2
Effective Date:	12/5/2025	Last Review Date:	11/18/2025
Applies to:	☒Illinois ☒Florida Kids	☒New Jersey ☒Pennsylvania Kids	☒Maryland ☒Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Zelsuvmi under the patient's prescription drug benefit.

Description:

FDA-Approved Indication
Zelsuvmi is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.

Applicable Drug List:

Zelsuvmi

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of molluscum contagiosum (MC)

AND

- The patient is 1 year of age or older

AND

- The requested drug will not be used on the same lesions for more than 12 weeks
  AND
  - The request is NOT for continuation of therapy

  OR
  - The request is for continuation of therapy

    AND
    - The patient has achieved or maintained a positive clinical response to the requested drug (e.g., clearance of or reduction in the number of lesions with prior treatment)

AND

- If additional quantities are being requested, then the requested drug is being prescribed to treat a number of lesions that requires more than 1 carton per 28 days.

Approval Duration and Quantity Restrictions:

Initial Approval: 3 Months
Renewal Approval: 12 Months

Quantity Level Limit: 1 carton per 28 days;

For a number of lesions requiring more than 1 carton per 28 days: 2 cartons per 28 days

References:

1. Zelsuvmi [package insert]. Wilmington, DE: EPIH SPV, LLC; January 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed July 16, 2025.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 07/16/2025).
4. Centers for Disease Control and Prevention. Molluscum contagiosum, April 15, 2025. https://www.cdc.gov/poxvirus/molluscum-contagiosum/. Accessed July 16, 2025.
5. American Academy of Dermatology Association. Molluscum contagiosum, March 10, 2025. https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview. Accessed July 16, 2024.
6. Hebert AA, Bhatia N, Del Rosso JQ. Molluscum contagiosum: epidemiology, considerations, treatment options, and therapeutic gaps. *J Clin Aesthet Dermatol*. 2023 Aug;16(8 Suppl 1):S4-S11.
7. Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. *J Am Acad Dermatol*. Published online October 5, 2023
8. U.S. Department of Health & Human Services. Burn Triage and Treatment – Thermal Injuries. Chemical Hazards Emergency Medical Management. Available at: https://chemm.hhs.gov/burns.htm. Accessed July 15, 2025.